Journal of Gastroenterology

, Volume 48, Issue 12, pp 1343–1352 | Cite as

Inhibition of lysosomal enzyme activities by proton pump inhibitors

  • Wensheng Liu
  • Susan S. Baker
  • Jonathan Trinidad
  • Alma L. Burlingame
  • Robert D. Baker
  • John G. Forte
  • Lauren P. Virtuoso
  • Nejat K. Egilmez
  • Lixin ZhuEmail author
Original Article—Alimentary Tract



Proton pump inhibitors (PPIs) are pro-drugs requiring an acidic pH for activation. The specificity of PPI toward the proton pump is mainly due to the extremely low pH at the parietal cell canalicular membrane where the pump is located. Reactivity of PPIs was also observed in moderately acidic environments like the renal collecting duct. But no PPI effect on lysosomal enzymes has been observed possibly because the previous studies were performed with liver tissue, where PPIs are metabolized.


The reactivity of PPIs (omeprazole, lansoprazole and pantoprazole) with a cysteine-containing peptide was analyzed by mass spectrometry, and the impact of PPIs on lysosomal enzymes was evaluated in cultured cells and mice. The effect of PPIs on the immune system was examined with a mouse tumor immunotherapy model.


Incubation of a cysteine-containing peptide with PPIs at pH5 led to the conversion of most of the peptide into PPI-peptide adducts. Dose dependent inhibition of lysosomal enzyme activities by PPIs was observed in cultured cells and mouse spleen. Further, PPI counteracted the tumor immunotherapy in a mouse model.


Our data support the hypothesis that many of the PPI adverse effects are caused by systematically compromised immunity, a result of PPI inhibition of the lysosomal enzymes. This novel mechanism complements the existing mechanisms in explaining the increased incidence of tumorigenesis and infectious diseases among PPI users and underlie the ongoing concern about the overuse of PPIs in adult and pediatric populations.


Omeprazole Lansoprazole Pantoprazole 



Acid phosphatase


Collision-induced dissociation


Gastroesophageal reflux disease






Proton pump inhibitors



This work was supported by a departmental start-up fund (to L.Z.). Mass spectrometry analysis was provided by the UCSF Mass Spectrometry Facility (A.L. Burlingame, Director) supported by the Biomedical Research Technology Program of the National Center for Research Resources, NIH NCRR RR001614 and NIH NCRR RR019934.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Bamberg P, Caswell CM, Frame MH, Lam SK, Wong EC. A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients. J Gastroenterol Hepatol. 1992;7:577–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol. 1995;7:467–75.PubMedGoogle Scholar
  3. 3.
    Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, et al. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther. 2001;15:917–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Gisbert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists—their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther. 2003;18:757–66.PubMedCrossRefGoogle Scholar
  5. 5.
    Welage LS. Overview of pharmacologic agents for acid suppression in critically ill patients. Am J Health Syst Pharm. 2005;62:S4–10.PubMedGoogle Scholar
  6. 6.
    Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother. 2001;35:1528–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:286–96.PubMedGoogle Scholar
  8. 8.
    Brandstrom A, Lindberg P, Bergman N-A, Alminger T, Ankner K, et al. Chemical reactions of omeprazole and omeprazole analogues. I. A survey of the chemical transformations of omeprazole and its analogues. Acta Chem Scand. 1989;B43:536–48.CrossRefGoogle Scholar
  9. 9.
    Mattsson JP, Vaananen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta. 1991;1065:261–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53:21–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006;79:76–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Burdan F, Siezieniewska Z, Maciejewski R, Madej B, Radzikowska E, et al. Hepatic lysosomal enzymes activity and liver morphology after short-time omeprazole administration. Exp Toxicol Pathol. 2002;53:453–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Fujisaki H, Oketani K, Nagakawa J, Takenaka O, Yamanishi Y. Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats. Jpn J Pharmacol. 1998;76:279–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Grinpukel S, Sewell R, Yeomans N, Mihaly G, Smallwood R. Lack of effect of omeprazole, a potent inhibitor of gastric (H+ + K+) ATPase, on hepatic lysosomal integrity and enzyme activity. J Pharm Pharmacol. 1986;38:158–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Trinidad JC, Thalhammer A, Specht CG, Lynn AJ, Baker PR, et al. Quantitative analysis of synaptic phosphorylation and protein expression. Mol Cell Proteomics. 2008;7:684–96.PubMedCrossRefGoogle Scholar
  16. 16.
    Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, et al. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol. 2006;177:6962–73.PubMedGoogle Scholar
  17. 17.
    Hill HC, Conway TF Jr, Sabel MS, Jong YS, Mathiowitz E, et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 2002;62:7254–63.PubMedGoogle Scholar
  18. 18.
    Terpstra AH. Differences between humans and mice in efficacy of the body fat lowering effect of conjugated linoleic acid: role of metabolic rate. J Nutr. 2001;131:2067–8.PubMedGoogle Scholar
  19. 19.
    Jalving M, Koornstra JJ, Wesseling J, Boezen HM, De Jong S, et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–8.Google Scholar
  20. 20.
    Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110:615–21.PubMedGoogle Scholar
  21. 21.
    Cats A, Schenk BE, Bloemena E, Roosedaal R, Lindeman J, et al. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Ekman L, Hansson E, Havu N, Carlsson E, Lundberg C. Toxicological studies on omeprazole. Scand J Gastroenterol Suppl. 1985;108:53–69.PubMedGoogle Scholar
  23. 23.
    Haga Y, Nakatsura T, Shibata Y, Sameshima H, Nakamura Y, et al. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor. Dig Dis Sci. 1998;43:253–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Dawson R, Manson JM. Omeprazole in oesophageal reflux disease. Lancet. 2000;356:1770–1.PubMedCrossRefGoogle Scholar
  25. 25.
    Hodgson N, Koniaris LG, Livingstone AS, Franceschi D. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc. 2005;19:1610–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Waldum HL, Gustafsson B, Fossmark R, Qvigstad G. Antiulcer drugs and gastric cancer. Dig Dis Sci. 2005;50(Suppl 1):S39–44.PubMedCrossRefGoogle Scholar
  27. 27.
    Jianu CS, Lange OJ, Viset T, Qvigstad G, Martinsen TC, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol. 2012;47:64–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sorensen HT, et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503–7.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 2011;60:624–30.PubMedCrossRefGoogle Scholar
  30. 30.
    Carter DC. Cancer after peptic ulcer surgery. Gut. 1987;28:921–3.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Caygill CP, Hill MJ, Kirkham JS, Northfield TC. Mortality from gastric cancer following gastric surgery for peptic ulcer. Lancet. 1986;1:929–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion. 1992;51(Suppl 1):102–14.PubMedCrossRefGoogle Scholar
  33. 33.
    Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8:571–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Doorduyn Y, Van Pelt W, Siezen CL, Van Der Horst F, Van Duynhoven YT, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008;136:1225–34.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Neal KR, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. BMJ. 1994;308:176.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007;5:1418–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, Wannet WJ, Van Pelt W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol Infect. 2006;134:617–26.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Neal KR, Scott HM, Slack RC, Logan RF. Omeprazole as a risk factor for campylobacter gastroenteritis: case–control study. BMJ. 1996;312:414–5.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047–56; quiz 2057.Google Scholar
  40. 40.
    Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(Suppl 2):S10–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784–90.PubMedCrossRefGoogle Scholar
  42. 42.
    Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170:772–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931–50.PubMedCrossRefGoogle Scholar
  44. 44.
    Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31:9–28.PubMedCrossRefGoogle Scholar
  45. 45.
    Andersson T, Olsson R, Regardh CG, Skanberg I. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clin Pharmacokinet. 1993;24:71–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Slattery E, Theyventhiran R, Cullen G, Kennedy F, Ridge C, et al. Intravenous proton pump inhibitor use in hospital practice. Eur J Gastroenterol Hepatol. 2007;19:461–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336:2–3.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM. 2008;101:445–8.PubMedCrossRefGoogle Scholar
  49. 49.
    van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther. 2009;29:571–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Gawron AJ, Rothe J, Fought AJ, Fareeduddin A, Toto E, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol. 2012;10:620–5.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Moore DJ, Tao BS, Lines DR, Hirte C, Heddle ML, et al. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr. 2003;143:219–23.PubMedCrossRefGoogle Scholar
  52. 52.
    Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(514–520):e514.CrossRefGoogle Scholar
  53. 53.
    Hassall E. Over-prescription of acid-suppressing medications in infants: how it came about, why it’s wrong, and what to do about it. J Pediatr. 2012;160:193–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Wensheng Liu
    • 1
  • Susan S. Baker
    • 1
  • Jonathan Trinidad
    • 2
  • Alma L. Burlingame
    • 2
  • Robert D. Baker
    • 1
  • John G. Forte
    • 3
  • Lauren P. Virtuoso
    • 4
  • Nejat K. Egilmez
    • 4
  • Lixin Zhu
    • 1
    • 5
    Email author
  1. 1.Women and Children’s Hospital of Buffalo and Department of PediatricsSUNY at BuffaloBuffaloUSA
  2. 2.Department of Pharmaceutical Chemistry, Mass Spectrometry FacilityUniversity of CaliforniaSan FranciscoUSA
  3. 3.Department of Molecular and Cell BiologyUniversity of CaliforniaBerkeleyUSA
  4. 4.Department of Microbiology and ImmunologySUNY at BuffaloBuffaloUSA
  5. 5.DDNC, Department of PediatricsSUNY at BuffaloBuffaloUSA

Personalised recommendations